Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

NCT04155918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout Patients

Interventions

DRUG: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
DRUG: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)

Sponsor

Arthrosi Therapeutics